{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Long+acting+insulin&page=2",
    "query": {
      "intervention": "Long acting insulin",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Long+acting+insulin&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T03:31:30.984Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00135057",
      "title": "Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "insulin glulisine",
          "type": "DRUG"
        },
        {
          "name": "insulin glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 281,
      "start_date": "2004-04",
      "completion_date": "2005-08",
      "has_results": false,
      "last_update_posted_date": "2011-01-11",
      "last_synced_at": "2026-09-27T03:31:30.984Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00135057"
    },
    {
      "nct_id": "NCT04542148",
      "title": "Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Preterm Birth",
        "Pregnancy, High Risk",
        "Diabetes, Gestational"
      ],
      "interventions": [
        {
          "name": "Sliding Scale Insulin",
          "type": "DRUG"
        },
        {
          "name": "Up-Titration of Home Insulin",
          "type": "DRUG"
        },
        {
          "name": "Continuous Insulin Infusion",
          "type": "DRUG"
        },
        {
          "name": "Dexcom G6 Professional Continuous Glucose Monitor",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "Up to 50 Years"
      },
      "enrollment_count": 120,
      "start_date": "2022-02-10",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-09-27T03:31:30.984Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Portland, Oregon • Greenville, South Carolina + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04542148"
    },
    {
      "nct_id": "NCT00384215",
      "title": "Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "insulin glargine [rDNA origin] injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 352,
      "start_date": "2001-12",
      "completion_date": "2005-02",
      "has_results": false,
      "last_update_posted_date": "2011-01-11",
      "last_synced_at": "2026-09-27T03:31:30.984Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00384215"
    },
    {
      "nct_id": "NCT02294474",
      "title": "Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "SAR342434",
          "type": "DRUG"
        },
        {
          "name": "Humalog",
          "type": "DRUG"
        },
        {
          "name": "insulin glargine HOE901",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 505,
      "start_date": "2015-01",
      "completion_date": "2016-02",
      "has_results": true,
      "last_update_posted_date": "2018-01-18",
      "last_synced_at": "2026-09-27T03:31:30.984Z",
      "location_count": 51,
      "location_summary": "Foley, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 45 more",
      "locations": [
        {
          "city": "Foley",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02294474"
    },
    {
      "nct_id": "NCT03330327",
      "title": "Molar Potency Study of HM12470 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "HM12470",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Hanmi Pharmaceutical Company Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 56,
      "start_date": "2015-03-30",
      "completion_date": "2017-08-17",
      "has_results": false,
      "last_update_posted_date": "2017-11-06",
      "last_synced_at": "2026-09-27T03:31:30.984Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03330327"
    },
    {
      "nct_id": "NCT00348972",
      "title": "Lantus in Prediabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hyperglycemia",
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Lantus® (insulin glargine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2002-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2006-07-06",
      "last_synced_at": "2026-09-27T03:31:30.984Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00348972"
    },
    {
      "nct_id": "NCT00574912",
      "title": "Characteristics of Glargine in Type 2 Diabetics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Insulin Glargine 0.5 u/kg body wt SC",
          "type": "DRUG"
        },
        {
          "name": "Insulin Glargine 1.0 u/kg body wt SC",
          "type": "DRUG"
        },
        {
          "name": "Insulin Glargine 1.5 u/kg body wt SC",
          "type": "DRUG"
        },
        {
          "name": "Insulin Glargine 2.0 u/kg body wt SC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2007-03",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2017-04-17",
      "last_synced_at": "2026-09-27T03:31:30.984Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00574912"
    },
    {
      "nct_id": "NCT00147745",
      "title": "Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Colesevelam",
          "type": "DRUG"
        },
        {
          "name": "Colesevelam matching placebo",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine (Lantus)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 36,
      "start_date": "2005-06",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2014-04-02",
      "last_synced_at": "2026-09-27T03:31:30.984Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00147745"
    },
    {
      "nct_id": "NCT01049412",
      "title": "A Study for Patients With Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "LY2605541",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 138,
      "start_date": "2010-01",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2018-04-17",
      "last_synced_at": "2026-09-27T03:31:30.984Z",
      "location_count": 10,
      "location_summary": "Chula Vista, California • Atlanta, Georgia • Idaho Falls, Idaho + 7 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Idaho Falls",
          "state": "Idaho"
        },
        {
          "city": "Topeka",
          "state": "Kansas"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01049412"
    },
    {
      "nct_id": "NCT01153100",
      "title": "Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "Glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "19 Years to 80 Years"
      },
      "enrollment_count": 60,
      "start_date": "2010-04",
      "completion_date": "2012-02",
      "has_results": false,
      "last_update_posted_date": "2019-11-01",
      "last_synced_at": "2026-09-27T03:31:30.984Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01153100"
    }
  ]
}